| scholarly article | Q13442814 |
| P356 | DOI | 10.1172/JCI107708 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC302653 |
| https://europepmc.org/articles/PMC302653?pdf=render | ||
| P932 | PMC publication ID | 302653 |
| P698 | PubMed publication ID | 4830223 |
| P5875 | ResearchGate publication ID | 18338877 |
| P2093 | author name string | P. J. Lachmann | |
| D. K. Peters | |||
| J. A. Charlesworth | |||
| D. G. Williams | |||
| E. Sherington | |||
| P2860 | cites work | Complement studies in membrano-proliferative glomerulonephritis | Q54310752 |
| Metabolism of radio-labelled C3: effects of in vivo activation in rabbits | Q68918643 | ||
| Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation | Q69377011 | ||
| The alternate pathway of complement activation. The role of C3 and its inactivator (KAF) | Q69382920 | ||
| Mesangiocapillary nephritis, partial lipodystrophy, and hypocomplementaemia | Q70000316 | ||
| A method of trace iodination of proteins for immunologic studies | Q70063670 | ||
| Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus | Q70405893 | ||
| Distribution and metabolism of I131 labeled proteins in man | Q74607843 | ||
| The theory of tracer experiments with 131I-labelled plasma proteins | Q74703080 | ||
| ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS | Q78397474 | ||
| Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection | Q24300424 | ||
| Glomerular deposition of properdin in acute and chronic glomerulonephritis with hypocomplementemia | Q34058375 | ||
| Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients | Q34089408 | ||
| Properdin and C3 Proactivator: Alternate Pathway Components in Human Glomerulonephritis | Q34500930 | ||
| The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum | Q36272793 | ||
| Inactivator of the Third Component of Complement as an Inhibitor in the Properdin Pathway | Q37496999 | ||
| Analysis of Disappearance Time-Curves After Single Injection of Labelled Proteins | Q39925681 | ||
| C3 proactivator convertase and its mode of action | Q42836051 | ||
| Isolation and properties of a glycine-rich β-glycoprotein of human serum | Q44467148 | ||
| Hypocomplementemia with cutaneous vasculitis and arthritis. Possible immune complex syndrome | Q44492309 | ||
| Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis | Q44511852 | ||
| Serum C'3 lytic system in patients with glomerulonephritis | Q44885697 | ||
| Chronic glomerulonephritis associated with low serum complement activity (chronic hypocomplementemic glomerulonephritis) | Q45031766 | ||
| C3 inactivating factor in the serum of a patient with chronic hypocomplementaemic proliferative glomerulo-nephritis | Q46300652 | ||
| Metabolism of the Third Component of Complement (C3) in Normal Human Subjects | Q47884717 | ||
| Increased Susceptibility to Infection in a Patient with Type II Essential Hypercatabolism of C3 | Q48014058 | ||
| The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. | Q54310041 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1578-1587 | |
| P577 | publication date | 1974-06-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Metabolic Studies of the Third Component of Complement and the Glycine-Rich Beta Glycoprotein in Patients with Hypocomplementemia | |
| P478 | volume | 53 |
| Q35498749 | A quantitative lateral flow assay to detect complement activation in blood |
| Q67529957 | Activation of the alternative complement pathway in systemic lupus erythematosus |
| Q67653052 | Acute hepatitis: significance of changes in complement components |
| Q37138770 | Alpha 1-antitrypsin deficiency, complement activation, and chronic liver disease |
| Q66884828 | C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus |
| Q72823186 | C3 metabolism in acute glomerulonephritis: implications for sites of complement activation |
| Q35201919 | C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase |
| Q67277366 | Change in serum properdin factor B phenotype following human orthoptic liver transplantation |
| Q58808226 | Circulating C3, C4, and C3 Split Products (C3c and C3d) During Normal Pregnancy* |
| Q37044336 | Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity |
| Q41035669 | Circulating immune complexes and C3d in human parasitosis |
| Q36616293 | Clinical application of a new nephelometric technique to measure complement activation |
| Q35196683 | Clinical significance of serum properdin levels and properdin deposition in the dermal-epidermal junction in systemic lupus erythematosus |
| Q39809852 | Clinical utility of complement assessment |
| Q68811673 | Complement (C3) metabolism in systemic lupus erythematosus in relation to the disease course |
| Q71294704 | Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus |
| Q37246497 | Complement activation by cellulosic dialysis membranes |
| Q33396528 | Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome |
| Q41731011 | Complement activation in asymptomatic patients with sickle cell anaemia |
| Q39429305 | Complement activation in migraine |
| Q67958586 | Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and factor B |
| Q41188610 | Complement activation in pneumonia |
| Q34860585 | Complement activation profiles in disease |
| Q45162825 | Complement and the clinician |
| Q35194351 | Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis |
| Q41365781 | Complement in cystic fibrosis |
| Q39487716 | Complement in the pathophysiology and diagnosis of human diseases |
| Q43724040 | Complement levels and C3 breakdown products in open-heart surgery: association of C3 conversion with the postpericardiotomy syndrome |
| Q70646458 | Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus |
| Q72114120 | Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity |
| Q43853170 | Correlations between serum factor B and C3b inactivator levels in normal subjects and in patients with infections, nephrosis and hypocomplementaemic glomerulonephritis. |
| Q41928296 | Cutaneous leishmaniasis: immune complex formation and necrosis in the acute phase |
| Q72122677 | Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes |
| Q70227589 | Development and clinical application of electroimmunoassays for the direct quantification of the complement C3 split products C3c and C3d |
| Q93523702 | Differences in the metabolism of C4 isotypes in patients with complement activation |
| Q72639251 | Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma |
| Q36130596 | Effects on serum complement of normal and pre-eclamptic pregnancy and of oral contraceptives |
| Q72631340 | Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins |
| Q41117627 | Experimental immune glomerulonephritis induced in the rabbit with streptococcal vaccine |
| Q24651118 | Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice |
| Q33890087 | Generation of complement protein C3 deficient pigs by CRISPR/Cas9-mediated gene targeting |
| Q69867245 | Genetically determined low C4: a predisposing factor to autoimmune chronic active hepatitis |
| Q57747428 | Hereditary C3 hypocomplementemia in the rabbit |
| Q34541825 | Human fibronectin metabolism |
| Q70567912 | Hypocomplementaemia due to a genetic deficiency of beta 1H globulin |
| Q44481073 | Hypocomplementemia in a newborn infant caused by placental transfer of C3 nephritic factor |
| Q39644143 | Identification of nephritic factor as an immunoglobulin |
| Q35887592 | Idiopathic membranoproliferative glomerulonephritis in childhood |
| Q40932039 | Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN) |
| Q74600355 | Infection in systemic lupus erythematosus |
| Q39714582 | Inherited deficiencies of complement in man |
| Q41878114 | Measles infection. Involvement of the complement system |
| Q67445830 | Membranoproliferative Nephritis and C3NeF |
| Q69633523 | Membranoproliferative glomerulonephritis, type II and partial lipodystrophy in an adult |
| Q71761794 | Meningococcal meningitis associated with persistent hypocomplementaemia due to circulating C3 nephritic factor |
| Q45246565 | Mesangiocapillary glomerulonephritis associated with meningococcal meningitis, C3 nephritic factor and persistently low complement C3 and C5. |
| Q52779350 | Metabolic studies of C3 in man |
| Q35817146 | Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis |
| Q66992247 | Metabolism of human beta 1H: studies in man and experimental animals |
| Q34482222 | Metabolism of properdin in normal subjects and patients with renal disease |
| Q37043934 | Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation |
| Q39537318 | Modulation of the properdin amplification loop in membranoproliferative and other forms of glomerulonephritis |
| Q70586995 | Molecular analysis of C3 allotypes in patients with nephritic factor |
| Q28317990 | Nephritic factor: Description of a new quantitative assay and findings in glomerulonephritis |
| Q67574406 | Normal complement in early poststreptococcal glomerulonephritis |
| Q69760964 | Opsonins and dysopsonins: an overview |
| Q39776393 | Pathogenesis and approaches to therapy of membranoproliferative glomerulonephritis |
| Q70228698 | Plasma C3d/C3 quotient as a parameter for in vivo complement activation |
| Q39688025 | Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus |
| Q68075258 | Relative value of serum C3 and C4 levels in predicting relapse in systemic lupus erythematosus |
| Q38724499 | Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal? |
| Q33433754 | Self-nonself discrimination by the complement system |
| Q44817225 | Serum immune complexes in membranoproliferative and other glomerulonephritides |
| Q44396159 | Significance of complement-positive Coombs test in patients with glomerular disease |
| Q70033141 | Skin lesions, angio-oedema, and hypocomplementaemia |
| Q67507672 | Studies in vivo of cobra factor and murine C3 |
| Q68370350 | Studies of serum complement in the hypocomplementaemic nephritides |
| Q67433383 | The Complement Abnormalities of Lipodystrophy |
| Q40487571 | The Complement System in Infectious Mononucleosis |
| Q40487563 | The Nail Patella Syndrome-A Report of a Family |
| Q67755681 | The cofactors required by C3 nephritic factor to generate a C3 convertase in vitro |
| Q69445277 | The complement system in type 1 (insulin-dependent) diabetes |
| Q40659228 | The in Vivo Metabolism of the Third Component of Complement in Systemic Lupus Erythematosus |
| Q33553504 | The in-vivo metabolism of C3 in ankylosing spondylitis |
| Q52767987 | The metabolism of C3 in adult coeliac disease. |
| Q70311157 | Thein vivometabolism of C3 in human glomerulonephritis and after renal transplantation |
Search more.